<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">Before the final definition of the commercial process, it could be advantageous to conduct a rigorous drug substance facility fit analysis with multiple contract manufacturing organizations (CMOs) and potential innovator company partners. The portability of the commercial process to enable production at 15,000â€“25,000 liters is an important requirement of a process that must be capable of supplying millions of doses in a short time or building up a stockpile of product. Multiple drug substance and drug product manufacturers may be required. A consortium of two or more companies sharing production capacity was proposed
 <sup>
  <xref ref-type="bibr" rid="CR25">25</xref>
 </sup> in 2006 and may be necessary to supply the large volume of product required.
</p>
